DOCSLIB.ORG

2020 ANNUAL REPORT Dear Shareholders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 ANNUAL REPORT Dear Shareholders annual report 2020 2020 CATALENT 2020 ANNUAL REPORT Dear Shareholders, In our fiscal year that ended on June 30, 2020, Catalent delivered record financial results, deploying our capabilities and expertise to generate robust organic growth, while keeping our employees safe and continuing to deliver for our customers and their patients. Our work has never been more seriousserious andand important,important, for for today today we we have have the the added added responsibility responsibility to to support support customers customers working on a range of responses to a global pandemic. This urgent need takes Catalent to a whole new level of “essential”—with speed, quality, and patient expectations like none that any of us has experienced in our careers. I couldn’t be prouder to be part of this industry, or of the Catalent team, but we’re also conscious of the enormous responsibilities ahead as a partner on over 50 COVID-19-related potential treatments and vaccines across all four of our business segments, including three Operation Warp Speed vaccine candidates. I am also pleased to report that S&P Dow Jones Indices has added Catalent to its S&P 500® index effective September 21, 2020. This designation is an affirmation of our strategy and the substantial progress we’ve made in executing it since our IPO in 2014. None of this would have been possible without the passion and dedication of our 14,000 employees, whose commitment to our mission to help people live better, healthier lives has propelled Catalent to where we are today. FISCAL 2019 IN REVIEW COVID-19 Response: Meeting the Needs of Employees, Customers, and Patients From the outset of the current pandemic, we had the northnorth starstar ofof ourour missionmission toto guideguide us,us, prioritizingprioritizing thethe safetysafety and well-being of our employees with a safe and secure workingworking environmentenvironment while,while, atat thethe samesame time,time, keepingkeeping ourour facilities open so that the vital medicinesmedicines andand healthhealth productsproducts wewe developdevelop andand produceproduce wouldwould remainremain availableavailable toto patients worldwide. Our COVID Response Team, led by Kay Schmidt,Schmidt, ourour seniorsenior vicevice presidentpresident ofof technicaltechnical operations,operations, mobilized early, implementing comprehensive safety protocols andand businessbusiness continuitycontinuity plansplans acrossacross ourour networknetwork ofof fifty sites. Our deep-rooted culture of GMP compliance, safety,safety, andand operationaloperational andand qualityquality excellenceexcellence gavegave usus anan advantage as we swiftly executed these activities. ToTo date,date, nonenone ofof ourour sitessites hashas experiencedexperienced anyany majormajor disruption,disruption, and we continue to work proactively with our customers andand supplierssuppliers toto maximizemaximize supplysupply chainchain continuity.continuity. Catalent was not only very well-positioned to weather this crisis, but, because of the transformative acquisitions we made over the last several years, combined with our strategic internal investments, capabilities, and expertise, we are now a “go-to” partner for COVID-19 response work. Nearly all our dosage forms are engaged with a COVID-19 treatment or vaccine candidate or clinical trial; and we are proud to have built the capability to provide multi-dose vial filling for potentially billions of COVID-19 vaccine doses, if needed. These important COVID-19 response programs illustrate our broad capabilities, both geographically and technologically, which are available not only for COVID 19 programs, but also for the increasingly wide range of products we manufacture on behalf of customers every year. Investing in Growth In fiscal 2020, we continued our transformative investments to shift our technology portfolio to even more innovative and in-demand areas of drug development and manufacturing, as well as investing significantly in capital projects to expand our capacity. We entered the cell therapytherapy marketmarket throughthrough our our acquisition acquisition of of Masthercell Masthercell Global, Global, a aleading leading cell cell therapy therapy contract contract developer and manufacturer withwith locationslocations in in Belgium Belgium and and Texas. Texas. We We expanded expanded our our Maryland-based Maryland-based gene gene therapy therapy business, including ourour flagshipflagship commercialcommercial manufacturingmanufacturing campus,campus, whichwhich becamebecame the the firstfirst contract contract development development and manufacturing site to secure FDA approval to Corporate Responsibility manufacture an approved gene therapy. Finally, we In lockstep with the growth and evolution of our acquired a first-class, biologics fill-finish, solid oral business is the continuing integration of our corporate dose, and packaging facility in Italy from Bristol- responsibility commitments into our operations and Myers Squibb to expand our European capabilities. culture. In April, we published our first Corporate Responsibility Report, covering fiscal 2019. It highlights We also increased our organic growth investments our commitment to a range of social and environmental in fiscal 2020 to meet customer and patient needs. topics related to our business, such as product quality, An outsized portion of the $466 million we spent on safety, environmental sustainability, and diversity capital improvements was directed to our biologic drug and inclusion. During these challenging times, I am substance and drug product offerings, including the proud to report that, under our Catalent Cares banner, aforementioned expansions in our gene therapy business participation in our Catalent Month of Service program and previously announced expansions of our biologics has doubled and the number of matching gift requests drug substance capacity in Madison, Wisconsin and our has tripled since those programs were launched a few biologics drug product capacity in Bloomington, Indiana. short years ago. We have also significantly expanded our These carefully conceived and timely executed investments corporate-level giving, helping with COVID-19 response led us to deliver robust growth in fiscal 2020, including and disasters around the world, as well as patient- and record double-digit organic net revenue growth, and have STEM-focused initiatives in our local communities. positioned our company for superior growth in the future. In the spring, we were all deeply affected by the senseless Financial Performance deaths of Black U.S. citizens. We stand with those who seek a world without bias or harmful discrimination, For fiscal 2020, Catalent delivered net revenue and and we at Catalent will continue to put our hearts and 1 Adjusted EBITDA organic growth rates above the high-end our actions into making our communities better and of our long-term targets of 8% and 11%, respectively. more inclusive. In our Corporate Responsibility Report, Fiscal 2020 net revenue grew 24%, compared to we shared that ethnically diverse talent represented 2 fiscal 2019 at constant exchange rates, to $3.1 33% of our U.S. workforce, and that 44% of global new billion, of which 12% was organic. Adjusted EBITDA hires were ethnically diverse. We will continue to train was $750.9 million for fiscal 2020, representing our Talent Acquisition teams on diverse recruitment constant-currency, organic growth of 14%, compared tactics, including forging partnerships with diverse to fiscal 2019. Adjusted Net Income per diluted professional organizations. We also took steps to 3 share was $2.11, compared to $1.81 in fiscal 2019. strengthen our ability to support diverse populations within our ranks by reinvigorating or starting several We also strengthened our balance sheet in fiscal 2020 employee resource groups, including groups focused on through several important financial transactions, veterans, members of the LGBTQ+ community, Latinos, including raising more than $1 billion through two women, young professionals, and employees of African public stock offerings. These strengthening actions ancestry or of Asian or Pacific Islander ancestry. significantly reduced our net leverage ratio and weighted average interest rate, while also extending the I look forward to our second Corporate Responsibility maturity profile of our debt. We ended the year with Report, covering fiscal 2020, later this year, which more than $950 million of cash and cash equivalents, will track our progress against environmental, social, compared to $345 million at the end of fiscal 2019, and governance metrics that align with the standards and reduced our net leverage ratio from 4.4x to 2.8x. set by the Sustainability Accounting Standards Board These actions provide Catalent with the flexibility to for the biotechnology and pharmaceutical sectors. invest for future growth, be it organic or inorganic. 1 For an explanation of how we determine Adjusted EBITDA, a non-GAAP measure, and how this financial measure reconciles to our reported results, please see pages 47 and 60-61 of the enclosed Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (our “2020 Form 10-K”). 2 Comparisons at “constant exchange rates” or in “constant currency” exclude the effects of foreign currency fluctuations against the U.S. dollar during the year. For a discussion of this non-GAAP measure and a reconciliation of constant-currency results to our reported results, please see pages 47 and 48 of our 2020
Load more

Recommended publications
  • Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • Curevac O Celonic Wi
    Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • CureVac o Celonic will manufacture 100 million doses of CureVac’s vaccine at its plant in Heidelberg, Germany, providing bulk substance for 50 million doses by the end of 2021. (press release) o Novartis will manufacture CureVac’s vaccine. (press release) o GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. (press release) o Rentschler Biopharma SE will manufacture CureVac’s vaccine. (press release) o Bayer will support the further development, supply and key territory operations of CureVac’s vaccine candidate. (press release) o Fareva will dedicate a manufacturing plant in France to the fill and finish of CureVac’s vaccine. (press release) o Wacker Chemie AG will manufacture CureVac’s vaccine candidate at its Amsterdam site. (press release) o CureVac will collaborate with Tesla Grohmann Automation to develop an RNA printer that works like a mini-factory and can produce such drugs automatically. (press release) • Moderna o Samsung Biologics will provide large scale, commercial fill-finish manufacturing for Moderna’s vaccine in South Korea. (press release) o Baxter International will provide fill/finish services and supply packaging for Moderna. (press release) o Sanofi will manufacture 200 million doses of Moderna’s COVID-19 vaccine starting in September 2021. (press release) o Rovi will produce bulk substance for Moderna’s COVID-19 vaccine, expanding an agreement between the companies.
    [Show full text]
  • COVID-19 Series
    Aug 2020 COVID-19 Series Research for Information and Discussion Purposes Only COVID-19 Series - Index Impact on Life Sciences Sector: 3-13 Response of the Life Sciences Industry:15-33 Charts & Insights: 35-55 Details of the Virus: 57-67 Research for Information and Discussion Purposes Only 2 For further details, please go to section: Global Spread of the Virus “Charts & Insights” The pandemic spreads incredibly quickly between people. More than 22m people infected in appr. 8 months 18 Aug 2020 Confirmed Cases: 22,096,857 Deaths: 772,523 The size of the bubble corresponds to the total confirmed deaths up to that date Source: Economist, FT Research for Information and Discussion Purposes Only 3 For further details, please go to section: Basics about SARS-CoV-2 & COVID-19 “Details of the Virus” Overview • Origin: Possibly in wet animal market in Wuhan, China • Disease: Coronavirus disease 2019 (COVID-19) • Cause: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) • Strain: Same virus as SARS-CoV-1, which affected 8,000 people in 2002-03 • DNA Study (Feb-2020): 96% DNA match between bat coronavirus and human suggests link to humans is not direct but through intermediate host • Target: Upper respiratory tract and can spread to lungs Transmission & Mechanism • Enters through nose, mouth, or eyes • Attaches to cells in the respiratory tract producing a protein called ACE2 • It fuses with the cell and releases the RNA • The hijacked infected cell will produce proteins based on the “instructions” from the virus’ RNA • Each infected
    [Show full text]
  • Cardinal Health 2019 Annual Report
    2019 Annual Report Essential to care ™ Corporate Offices Cardinal Health 7000 Cardinal Place Dublin, Ohio 43017 614.757.5000 www.cardinalhealth.com © 2019 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks of Cardinal Health and may be registered in the US and/or in other countries. All other marks are the property of their respective owners. Lit. No. 5CR19-971925 (08/2019) DearDear fellow fellow shareholders: shareholders: CorporateCorporate and and In myIn my letter letter to toyou you last last year, year, I acknowledged I acknowledged investorinvestor information information thethe trust trust you you place place in usin usto torun run the the business business CorporateCorporate offices offices FinancialFinancial information information effectivelyeffectively and, and, in inturn, turn, be beresponsible responsible CardinalCardinal Health Health ComprehensiveComprehensive financial financial and andother other information information about about stewardsstewards of ofyour your capital. capital. I’d I’dlike like to toshare share with with 70007000 Cardinal Cardinal Place Place CardinalCardinal Health Health can can be obtainedbe obtained by visiting by visiting the theInvestor Investor Dublin,Dublin, Ohio Ohio 43017 43017 RelationsRelations page page at ir.cardinalhealth.com. at ir.cardinalhealth.com. youyou some some of ofour our accomplishments accomplishments over over 614.757.5000614.757.5000 thethe past past year year and and where where we we are are going going
    [Show full text]
  • Catalent, Inc. Annual Report 2019
    Catalent, Inc. Annual Report 2019 Form 10-K (NYSE:CTLT) Published: August 27th, 2019 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-K ______________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 ___________________________ CATALENT, INC. (Exact name of registrant as specified in its charter) ______________________________ Delaware 20-8737688 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 14 Schoolhouse Road 08873 Somerset, New Jersey (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 537-6200 ______________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share CTLT New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None ______________________________ Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Cardinal Health 2018 Proxy Statement
    2018 Proxy Statement Notice of Annual Meeting of Shareholders Letter to Cardinal Health Shareholders 1 Notice of Annual Meeting of Shareholders 3 Proxy Summary 4 Fiscal 2018 Highlights 4 Governance and Board Highlights 4 Our 2018 Board Nominees 5 Addressing the Opioid Crisis 6 Attending the Annual Meeting of Shareholders 8 Roadmap to Voting Matters 8 How to Vote 8 Corporate Governance 9 Proposal 1 — Election of Directors 9 Board Membership Criteria: What we look for 9 Our Director Nominees 9 Our Board’s Composition and Structure 15 Our Board’s Primary Role and Responsibilities and Processes 19 Shareholder Engagement 21 Director Compensation 22 Related Person Transactions Policy and Process 23 Audit Committee Matters 24 Proposal 2 — Ratification of Appointment of Ernst & Young LLP as Independent Auditor 24 Audit Committee Report 24 Fees Paid to Ernst & Young LLP 25 Policy on Pre-Approval of Services Provided by Ernst & Young LLP 25 Executive Compensation 26 Proposal 3 — Advisory Vote to Approve the Compensation of Our Named Executive Officers 26 Compensation Discussion and Analysis 27 Human Resources and Compensation Committee Report 34 Executive Compensation Tables 35 Pay Ratio Disclosure 48 Shareholder Proposals 49 Proposal 4 — Shareholder Proposal on a Policy to Not Exclude Legal and Compliance Costs for Purposes of Determining Executive Compensation 49 Proposal 5 — Shareholder Proposal on the Ownership Threshold for Calling a Special Meeting of Shareholders 51 Share Ownership Information 52 Beneficial Ownership 52 Compliance with Section 16(a) of the Exchange Act 53 Other Matters 54 General Information About the Annual Meeting of Shareholders 54 Communicating with the Board 56 Shareholder Recommendations for Director Nominees 56 Submitting Proxy Proposals and Director Nominations for the Next Annual Meeting of Shareholders 56 Corporate Governance Guidelines 57 Transfer Agent 57 Other Information 57 Annex A — Use of Non-GAAP Financial Measures 58 strong leadership and commitment to Cardinal Health during his Letter to Cardinal tenure.
    [Show full text]
  • Cardinal Health, Inc. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) Ohio 31-0958666 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 7000 Cardinal Place, Dublin, Ohio 43017 (Address of principal executive offices) (Zip Code) (614) 757-5000 (Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
    [Show full text]
  • 2008 Annual Report
    essential to care Annual Report 2008 In today’s complex world of healthcare, safe and efficient care is not optional. It is essential. At Cardinal Health, we work with hospitals and pharmacies across the globe every day to improve the safety and productivity of the care they provide. Long before a patient arrives at a hospital for treatment or calls a pharmacy for a prescription, Cardinal Health is an essential part of delivering safe and eff icient care. We provide the medical technologies that help ensure safe doses of critical medications at the bedside. Our surgical gloves help protect both caregivers and patients from infections. We deliver medicine to pharmacies, so it is ready to be dispensed at a moment’s notice. These are just a few examples of how Cardinal Health is essential to care. But it is not enough to provide the products and services that are essential in today’s healthcare system. At Cardinal Health, essential to care means: Caring about our customers. Caring about patient outcomes. Caring about employees. Caring about shareholders. Caring about our communities. Essential to care. It is the driving force behind Cardinal Health’s mission of making healthcare safer and more productive. Chairman’s letter To our customers, employees and shareholders: In the United States and around the world, the cost of to do: help sick patients get better. That’s why we believe delivering healthcare continues to accelerate. I believe that that no company is better positioned than Cardinal Health one of the keys to driving a meaningful reduction in the cost to streamline the healthcare supply chain, help clinicians of care is improving the quality of care.
    [Show full text]
  • GAO-21-443, COVID-19: Efforts to Increase Vaccine Availability And
    United States Government Accountability Office Report to Congressional Addressees April 2021 COVID-19 Efforts to Increase Vaccine Availability and Perspectives on Initial Implementation GAO-21-443 April 2021 COVID-19 Efforts to Increase Vaccine Availability and Perspectives on Initial Implementation Highlights of GAO-21-443, a report to congressional addressees Why GAO Did This Study What GAO Found Providing the public with safe and The federal government has taken several actions to increase the availability of effective vaccines to prevent COVID- COVID-19 vaccine doses and indicated it expects to have enough doses 19 is crucial to mitigating the public available for all adults in the United States by the end of May. As of April 1, 2021, health and economic impacts of the the government had purchased 1.2 billion doses of one- and two-dose regimen disease. The U.S. had almost 30 vaccines. Also, vaccine companies reported making additional manufacturing million reported cases and over sites operational, among other actions to expand capacity and mitigate 545,000 reported deaths as of March challenges. 27, 2021. The federal government took a critical step in December 2020 in Federal officials said projecting future availability of vaccine doses can be authorizing the first two COVID-19 difficult, in part because of uncertainty surrounding complex manufacturing vaccines and beginning distribution of processes. Given this uncertainty, coupled with the significant manufacturing and doses across the nation. The distribution increases needed to have enough vaccine doses available for all government had distributed about adults, managing public expectations is critical. GAO’s prior work has found that 180.6 million vaccine doses, and about timely, clear, and consistent communication about vaccine availability is essential 147.8 million doses had been to ensure public confidence and trust, especially as initial vaccine implementation administered, as of March 27, 2021, did not match expectations.
    [Show full text]
  • Vaccine Manufacturing Collaborations
    WORKING TOGETHER TO FIGHT COVID-19: VACCINE MANUFACTURING COLLABORATIONS Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 vaccine manufacturing. Companies are working to source needed raw materials and other supplies and increasing manufacturing capacity to get COVID-19 vaccine shots in as many arms as possible. Even prior to knowing the efficacy of particular vaccine candidates, companies have proactively been increasing their own manufacturing capabilities as well as partnering with other manufacturers who are sharing available capacity to support production. These partnerships have been key to manufacturing ramp-up following vaccine authorization. MANUFACTURING PROCESS Manufacturing vaccines on a global scale is a highly specialized and intensive bioprocess given that COVID-19 vaccines are complex biologic products. At a high level, the manufacturing process falls into six critical phases and biopharmaceutical companies are lending a hand at every step: Raw Material Active Coupling & Packaging & Shipment & Filling Reception Ingredient Formulation Lot Releases Distribution RECENT EXAMPLES OF PhRMA MEMBER Bayer COMPANY VACCINE MANUFACTURING Bayer and CureVac are partnering to manufacture CureVac’s COLLABORATIONS INCLUDE: mRNA-based COVID-19 vaccine. Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information and AstraZeneca supply chain performance as well as support in selected
    [Show full text]
  • GCSG 2020 Global Virtual Conference Registrant List
    GCSG 2020 Global Virtual Conference Registrant List First Name Last Name Attendee company Attendee country Beth Adams Takeda United States Robert Adriaansen Berlinger & Co. AG Netherlands Christopher Allaire Clovis Oncology United States Deb Allwine Global Clinical Connections United States Alexi Anderson Regeneron United States David Antieau Zymeworks United States Kingsley Asam-Dankwah Bristol-Myers Squibb United States Andrew Atchley Arena Pharmaceuticals United States Steven Awad Johnson & Johnson United States Natalie Balanovsky Almac Group United States Jennifer Banh MyoKardia United States Jim Bannister Clinigen Group United States Lindsay Belcher Cryoport United States Melanie Bell SciLucent Inc. United States Harry Berlanga Thermofisher United Kingdom Sashin Bhuta Bristol-Myers Squibb United States Katie Bielat Apellis Pharmaceuticals United States William Birecree Bausch Health Companies United States Marcel Bizien VA Cooperative Studies Program United States Michelle Blandin Molecular Templates United States Alena Bolazeva Bristol Myers-Squibb Belgium Allen Bolden BDO USA, LLP (BPTG) United States Richard Bolnick Citation Healthcare Labels United States Bruce Bowman Marken Clinical Trial Logistics United States Caitlin Bowne Alkermes United States Ted Bradley Pfizer United States Tom Brady Xerimis United States Fadoua Braz Eli Lilly United States George Brennan ThermoFisher Scientific United States Lorna Briddick Brizzey United States William Brocious Eli Lilly United States Chris Brown QED Therapeutics United States Gerard Brown 4G Clinical United States Lisa Brown Mylan Pharmaceuticals United States Kimberly Buchanan Merck United States Andrew Buckley Takeda United States Jennifer Bulthuis Pfizer United States Cristine Burfeind United Therapeutics United States Kristi Byrnes Agios Pharmaceuticals United States Carolyn Cammarano Agios Pharmaceuticals United States Ana-Zeralda Canals Debiopharm International S.A.
    [Show full text]
  • Cardinal Health 2020 Annual Report
    2020 Annual Report Dear fellow shareholders, A year ago, I closed my letter to you with a reflection on our role in healthcare. Over the past several months, we have seen that now more than ever, what we do matters — to our customers, to the patients they serve, and to our communities. In my nearly 30 years as part of the Cardinal Health family, I have experienced significant transformation, both within our company and within the healthcare industry. We have expanded our products, services and markets, evolved with technological and regulatory changes, and adapted in the face of external challenges. In each of these moments, we have demonstrated agility and embraced change to emerge as a stronger company with an even more solidified role in healthcare. Now, as we navigate the unprecedented challenges of a global pandemic, we are leaning on that legacy of adaptability and dedication. In fiscal 2020, we delivered on our commitments and continued to execute on our long-term strategic priorities, all as we adapted our operations to address the unique challenges presented by COVID-19. Our fiscal 2020 financial performance Across the company, in fiscal 2020, we demonstrated positive In the Medical segment, our cost savings initiatives, performance despite significant global challenges. We grew particularly within our global manufacturing and supply non-GAAP operating earnings, exceeded our non-GAAP chain, drove significant benefits throughout the year. We EPS guidance range, surpassed our cost savings target, and expect these workstreams to continue to deliver greater strengthened our balance sheet. In the year, we invested $375 efficiencies and additional value into the future.
    [Show full text]
  • Corporate Citizenship Report 2019 Table of Contents
    Corporate Citizenship Report 2019 Table of contents Editor’s note: This report was largely created before the COVID-19 pandemic. During the pandemic, we at Cardinal Health are working around the clock to meet the needs of healthcare providers so they can safely serve the patients who depend on them. Learn about our response » A message to our stakeholders ______________________________ 3 Creating value for our customers and our partners ����������27 Essential to care™ _________________________________________ 7 Strengthening our communities _________________________41 Our Path Forward ________________________________________ 8 Operating sustainably and responsibly ____________________48 ESG management and governance __________________________ 9 Governance and ethics _________________________________56 Stakeholder engagement _________________________________ 11 About this report _______________________________________ 63 Empowering our people ________________________________ 12 GRI index _____________________________________________ 64 Table of contents Our people Customers and partners Our communities Sustainability Governance GRI index 2019 Corporate Citizenship Report | 2 A message to our stakeholders This Corporate Citizenship Report was nearly complete when the COVID-19 pandemic changed the world in ways no one could ever have imagined. So I am beginning this letter differently than I originally planned. First, I want to express my deepest gratitude to every frontline worker and healthcare professional around the globe. The courage and commitment you bring to work with you every day is awe-inspiring. Your work is making a difference. Thank you. Since early March, the 48,000 Cardinal Health employees around the we have significantly expanded our technology infrastructure to help world have been more focused than ever before on delivering the employees around the globe continue to support customers, patients products and solutions that improve the lives of people every day.
    [Show full text]